drugset / Trial / NCT02264015
Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
Incidence of visual phenomena, heart rate at rest, safety (with particular emphasis on QT analysis of ECGs), and pharmacokinetic parameters
Timeline
- Start
- 2004-01
- Primary completion
- 2004-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cilobradine | Small molecule | 2 mg | Oral |
| Subject | Cilobradine | Small molecule | 5 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
Indications
No indication recorded.